AR018272A1 - Una composicion oftalmica para el tratamiento de las lesiones de la cornea causadas por diabetes y/o para el tratamiento de la estesia de la corneadeteriorada y el uso del ingrediente activo de dicha composicion para la preparacion de dicha composicion oftalmica. - Google Patents
Una composicion oftalmica para el tratamiento de las lesiones de la cornea causadas por diabetes y/o para el tratamiento de la estesia de la corneadeteriorada y el uso del ingrediente activo de dicha composicion para la preparacion de dicha composicion oftalmica.Info
- Publication number
- AR018272A1 AR018272A1 ARP990100399A ARP990100399A AR018272A1 AR 018272 A1 AR018272 A1 AR 018272A1 AR P990100399 A ARP990100399 A AR P990100399A AR P990100399 A ARP990100399 A AR P990100399A AR 018272 A1 AR018272 A1 AR 018272A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- composition
- diabetes
- active ingredient
- corneal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se revela una composicion oftálmica, util para el tratamiento de las lesiones de la cornea causadas por diabetes y/o para el tratamiento de la estesiade la cornea deteriorada. Dicha composicion comprende, como ingrediente activo, un compuesto que sepresenta por la formula general (I), en la cual A y B sonindependientemente alquileno inferior; X, Y y Z son independientemente halogeno, o una de sus sales farmacologicamente aceptable. Además, lacomposicion oftálmica de la presente invencion se usapara tratar las lesiones de la cornea no causadas por diabetes, para el tratamiento del síndromede ojo seco, y/o para el tratamiento del hipolagrimeo, que comprende, como un ingrediente activo, un inhibidor de la reductasa de aldosa. Las composicionesoftálmicas de la presente invencion son efectivas para el tratamiento de, por lo menos, una enfermedad seleccionada entre lesiones de la cornea, estesia de lacornea deteriorada, síndrome de ojo seco e hipolagrimeo
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1983698 | 1998-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR018272A1 true AR018272A1 (es) | 2001-11-14 |
Family
ID=12010371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990100399A AR018272A1 (es) | 1998-01-30 | 1999-02-01 | Una composicion oftalmica para el tratamiento de las lesiones de la cornea causadas por diabetes y/o para el tratamiento de la estesia de la corneadeteriorada y el uso del ingrediente activo de dicha composicion para la preparacion de dicha composicion oftalmica. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6403598B1 (es) |
| EP (2) | EP1161942A3 (es) |
| KR (1) | KR20010040457A (es) |
| CN (1) | CN1295476A (es) |
| AR (1) | AR018272A1 (es) |
| AT (1) | ATE223219T1 (es) |
| AU (1) | AU2184499A (es) |
| BR (1) | BR9907715A (es) |
| CA (1) | CA2318516A1 (es) |
| DE (1) | DE69902738T2 (es) |
| HU (1) | HUP0100214A3 (es) |
| IL (1) | IL137128A0 (es) |
| NO (1) | NO20003786D0 (es) |
| TR (1) | TR200002209T2 (es) |
| WO (1) | WO1999038497A2 (es) |
| ZA (1) | ZA99733B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2129500A (en) * | 1999-01-25 | 2000-08-07 | Fujisawa Pharmaceutical Co., Ltd. | Eye drops |
| WO2001085183A2 (en) * | 2000-05-08 | 2001-11-15 | N.V. Nutricia | Preparation for the prevention and treatment of ocular disorders |
| DE10045343B4 (de) * | 2000-09-14 | 2005-05-12 | Neuhann, Tobias, Dr.med. | Verwendung einer wässrigen Lösung oder Suspension zum Heilen des Hornhautepithels |
| NZ537735A (en) * | 2002-07-03 | 2006-08-31 | Pericor Science Inc | Compositions of hyaluronic acid and methods of use |
| EP1757603A4 (en) * | 2004-05-11 | 2008-06-25 | Santen Pharmaceutical Co Ltd | THERAPEUTIC AGENT FOR KERAATOCONJUNCTIVITIS AFFECTION |
| US20060275278A1 (en) * | 2005-06-02 | 2006-12-07 | Choy Camus K M | Method and ophthalmic formulation for eye protection or treatment |
| US7247623B2 (en) * | 2005-08-19 | 2007-07-24 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with non-drying antihistamines |
| PE20070823A1 (es) * | 2005-11-15 | 2007-08-09 | Glaxo Group Ltd | Sal tosilato de 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2-hidroxi-1-(hidroximetil)etil]amino}pirido[2,3-]pirimidin-7(8h)-ona |
| US8158667B2 (en) | 2006-08-21 | 2012-04-17 | Kador Peter F | Topical treatment of cataracts in dogs |
| US20090093446A1 (en) * | 2007-10-05 | 2009-04-09 | Winston Laboratories, Inc. | Method for alleviating keratoconjunctivitis sicca |
| WO2015095515A1 (en) * | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
| AR108280A1 (es) * | 2016-05-05 | 2018-08-08 | Acraf | Composición oftálmica que comprende una combinación sinérgica de glucógeno y ácido hialurónico o sal del mismo |
| CN111629730A (zh) * | 2017-08-24 | 2020-09-04 | 加利福尼亚大学董事会 | 眼部药物组合物 |
| US11166925B2 (en) | 2018-08-23 | 2021-11-09 | Elorac, Inc. | Method for alleviating keratoconjunctivitis sicca |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474967A (en) | 1983-04-27 | 1984-10-02 | Pfizer Inc. | 8-Deutero and 8-tritio-substituted derivatives of D-4S-6-fluoro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione |
| JPS6143114A (ja) | 1984-08-03 | 1986-03-01 | Takeda Chem Ind Ltd | 虹彩・毛様体疾患治療用眼局所投与剤 |
| GB8524663D0 (en) * | 1985-10-07 | 1985-11-13 | Fujisawa Pharmaceutical Co | Quinazoline derivatives |
| US5360611A (en) * | 1988-10-03 | 1994-11-01 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation |
| JPH0782259A (ja) | 1993-09-14 | 1995-03-28 | Senju Pharmaceut Co Ltd | スクシンアミド酸誘導体及びそれを含有する糖尿病合併症治療剤 |
-
1999
- 1999-01-29 US US09/485,414 patent/US6403598B1/en not_active Expired - Fee Related
- 1999-01-29 EP EP01115994A patent/EP1161942A3/en not_active Withdrawn
- 1999-01-29 CN CN99804408A patent/CN1295476A/zh active Pending
- 1999-01-29 ZA ZA9900733A patent/ZA99733B/xx unknown
- 1999-01-29 KR KR1020007008301A patent/KR20010040457A/ko not_active Application Discontinuation
- 1999-01-29 CA CA002318516A patent/CA2318516A1/en not_active Abandoned
- 1999-01-29 TR TR2000/02209T patent/TR200002209T2/xx unknown
- 1999-01-29 WO PCT/JP1999/000369 patent/WO1999038497A2/en not_active Application Discontinuation
- 1999-01-29 AU AU21844/99A patent/AU2184499A/en not_active Abandoned
- 1999-01-29 AT AT99901903T patent/ATE223219T1/de not_active IP Right Cessation
- 1999-01-29 HU HU0100214A patent/HUP0100214A3/hu unknown
- 1999-01-29 DE DE69902738T patent/DE69902738T2/de not_active Expired - Fee Related
- 1999-01-29 IL IL13712899A patent/IL137128A0/xx unknown
- 1999-01-29 EP EP99901903A patent/EP1004307B1/en not_active Expired - Lifetime
- 1999-01-29 BR BR9907715-9A patent/BR9907715A/pt not_active IP Right Cessation
- 1999-02-01 AR ARP990100399A patent/AR018272A1/es unknown
-
2000
- 2000-07-24 NO NO20003786A patent/NO20003786D0/no not_active Application Discontinuation
-
2002
- 2002-04-29 US US10/133,450 patent/US6476039B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010040457A (ko) | 2001-05-15 |
| WO1999038497A2 (en) | 1999-08-05 |
| DE69902738T2 (de) | 2003-02-06 |
| BR9907715A (pt) | 2000-10-17 |
| DE69902738D1 (de) | 2002-10-10 |
| CN1295476A (zh) | 2001-05-16 |
| WO1999038497A3 (en) | 2000-03-09 |
| IL137128A0 (en) | 2001-07-24 |
| US6403598B1 (en) | 2002-06-11 |
| EP1004307A2 (en) | 2000-05-31 |
| CA2318516A1 (en) | 1999-08-05 |
| NO20003786L (no) | 2000-07-24 |
| HUP0100214A2 (hu) | 2002-02-28 |
| ATE223219T1 (de) | 2002-09-15 |
| NO20003786D0 (no) | 2000-07-24 |
| US20020161015A1 (en) | 2002-10-31 |
| HUP0100214A3 (en) | 2002-10-28 |
| EP1161942A2 (en) | 2001-12-12 |
| EP1161942A3 (en) | 2003-12-10 |
| US6476039B1 (en) | 2002-11-05 |
| AU2184499A (en) | 1999-08-16 |
| EP1004307B1 (en) | 2002-09-04 |
| ZA99733B (en) | 1999-08-02 |
| TR200002209T2 (tr) | 2000-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR018272A1 (es) | Una composicion oftalmica para el tratamiento de las lesiones de la cornea causadas por diabetes y/o para el tratamiento de la estesia de la corneadeteriorada y el uso del ingrediente activo de dicha composicion para la preparacion de dicha composicion oftalmica. | |
| ECSP055781A (es) | Composiciones oftálmicas para el tratamiento de la hipertensión ocular | |
| GT200000038A (es) | Inhibidores de la sorbitol deshidrogenasa. | |
| BRPI0508876A (pt) | pró medicamentos de agentes antivirais de piperazina e piperidina substituìda | |
| CY1109117T1 (el) | Διαμορφωσεις enaιωphmatoς, οι οποιες περιλαμβανουν δραστικον συστατικο, επιφανειακως δρωσαν ουσια poloxamer ή meroxapol και γλυκολη, χρησις του δια την βιομηχανικην παρασκευην φαρμακου προς νοσηλειαν οφθαλμικων διαταραχων | |
| CU23208A3 (es) | Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea | |
| BR0317572A (pt) | Benzoxazinas e seus derivados como inibidores de pi3ks | |
| BR0107811A (pt) | Composição herbicida | |
| BRPI0412348A (pt) | derivados de piperazina e seu uso como agentes terapêuticos | |
| BRPI0511874A (pt) | derivados da pirrolopiridina | |
| BR0312232A (pt) | Inibidores de caspases e seus usos | |
| GT200300294A (es) | Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso | |
| HN2004000383A (es) | "derivados de tropano" | |
| UY29412A1 (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos. | |
| CY1108676T1 (el) | Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχων | |
| NI200300053A (es) | Derivados del tropano utiles en terapia. | |
| UY29802A1 (es) | Análogos de la feniletilamina y su uso en el tratamiento del glaucoma | |
| BR0209327A (pt) | Composição para tratamento de constipação induzida por drogas | |
| DK0868909T3 (da) | Opthalmisk bæreropløsning | |
| BRPI0607214B8 (pt) | derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação | |
| AR032138A1 (es) | Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma | |
| RU2008102249A (ru) | Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания | |
| BR0208353A (pt) | Compostos de diidropirimidina substituìdos com ciano e seu uso para tratar doenças | |
| AR041942A1 (es) | Derivados de 10-oxa -1-aza-dibenzo [a,d] ciclohepteno-7-carboxilico como antagonistas ccr1 para el tratamiento de la enfermedad desmielinizante inflamatoria | |
| DE60106953D1 (de) | Adenosinderivate und deren verwendung |